12:00 AM
Aug 31, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xolair omalizumab regulatory update

Novartis said the EC approved an expanded label for Xolair omalizumab to include use as an add-on therapy to improve asthma control in...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >